RESULTS OF CONGENITAL HEART DISEASES CORRECTION BY MEANS OF BIOPROSTHESES FROM GLISSON'S BOVINE CAPSULE
Introduction. Biological heart valves are widely used in patients with tricuspid valve lesions, and considered to be the “prostheses of choice” by most surgeons. However, the long-term functional durability due to biological material degeneration and calcification has always been and still is an issue. It deserves further search for a better source of material for leaflet manufacturing. Aim of the study is to demonstrate the results of the tricuspid valve replacement (TVR) with biological valve made of Glisson's bovine capsule - Bioglis - in patients with congenital heart diseases in the early and late follow-up (more than 10 years after implantation). Material and methods. From 1997 till 2014 in The Bakulev Scientific Center for Cardiovascular Surgery 104 patients with tricuspid valve diseases underwent TVR with biological prostheses Bioglis. For reference, 52 patients with conventional xenopericardium Bionics' valves were examined. Results. Comparative evaluation of the functional and hemodynamic status immediately after surgery and in early postoperative period did not reveal any significant differences between both groups of patients by both the incidence of complications and the severity of the postoperative period and prosthesis function. In late follow-up, in Bioglis group, most patients meet I-II NYHA functional class. Unsatisfying results of correction were observed in 11.6% of patients due to infective endocarditis and paravalvular leaks. Conclusion. The study of both groups of patients in 10 years after TVR revealed advantage of Glisson' capsule as a material, which is more durable, more resistant to degeneration and calcification. From the data of more than 10 years of clinical observation, as well as from previously performed in vitro and in vivo clinical studies of Glisson's bovine capsule it may be concluded that Bioglis prostheses have much in favour for preferable use in correction congenital and acquired heart diseases.